drugset / Trial / NCT00478231

Multicenter, Safety Study Of Maraviroc

NCT00478231

Phase 3 Completed 209 enrolled ViiV Healthcare Pfizer · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.

Timeline

Start
2007-07
Primary completion
2010-08
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified

Indications